Applying guidelines-directed therapies for antiplatelets and antithrombotics requires balancing the risks of cardiovascular events and the risk of bleeding. Guest Erin Michos, MD, MHS, FACC, FAHA, FASE, FASCP, describes the use shared decision-making with patients who are at higher risk for thrombotic events, and discusses pharmacotherapies recommended for use with particular patient groups.
2019 AHA/ACC Primary Prevention Guidelines: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000678
US Preventive Service Task Force 2022 Aspirin Recommendations: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication
CURE Trial 2022: https://www.ahajournals.org/doi/10.1161/01.cir.0000029926.71825.e2
DAPT risk calculator: https://tools.acc.org/daptriskapp/#!/content/calculator/
PRECISE-DAPT score: http://www.precisedaptscore.com/predapt/
TWILIGHT trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1908419
2021 AHA/ACC/SCAI guidelines for acute coronary disease: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001038
COMPASS trial: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046048
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
